Page last updated: 2024-12-05
4,4'-diaminodibenzyl
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Market Indicators
Description
4,4'-Diaminodibenzyl (DADB) is a diamine compound with the chemical formula C14H16N2. It is a colorless solid that is soluble in organic solvents. DADB is synthesized through the reduction of 4,4'-dinitrodibenzyl, which can be obtained through the nitration of dibenzyl. DADB has been investigated for its potential applications in various fields, including: polymers, pharmaceuticals, and electronics. It has shown promising properties as a curing agent for epoxy resins, a precursor for the synthesis of polyamides, and a component in the development of organic semiconductors. Research into DADB focuses on exploring its reactivity, its ability to form complexes with metal ions, its potential as a building block for functional materials, and its use in the development of new technologies.'
4,4'-diaminodibenzyl: RN given refers to parent cpd [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
| ID Source | ID |
|---|---|
| PubMed CID | 12138 |
| CHEMBL ID | 1704183 |
| SCHEMBL ID | 187043 |
| MeSH ID | M0097228 |
Synonyms (63)
| Synonym |
|---|
| smr000476340 |
| MLS001180989 |
| 4,4'-ethylenebis(aniline) |
| aniline, p,p'-ethylenedi- |
| brn 0394999 |
| nsc 44062 |
| nsc 60033 |
| nsc 580 |
| einecs 210-716-7 |
| aniline, 4,4'-ethylenedi- |
| alpha,alpha'-bi-p-toluidine |
| 4,4'-diaminodibenzyl |
| ccris 1004 |
| BB 0221264 |
| benzenamine, 4,4'-(1,2-ethanediyl)bis- |
| nsc-44062 |
| nsc44062 |
| nsc60033 |
| nsc-60033 |
| 4-[2-(4-aminophenyl)ethyl]phenylamine |
| AH-034/32835045 |
| OPREA1_504832 |
| CBDIVE_013839 |
| alpha, alpha-bi-p-toluidine |
| 4-[2-(4-aminophenyl)ethyl]aniline |
| 621-95-4 |
| nsc580 |
| .alpha.,.alpha.'-bi-p-toluidine |
| nsc-580 |
| aniline,4'-ethylenedi- |
| 1,2-bis(4-aminophenyl)ethane |
| 4,4'-diaminobibenzyl |
| 1,2-bis(p-aminophenyl)ethane |
| benzenamine,4'-(1,2-ethanediyl)bis- |
| 4,4'-ethylenedianiline |
| 4,4'-ethylenedianiline, technical, >=95% (nt) |
| STL089722 |
| 4,4'-ethane-1,2-diyldianiline |
| 4,4'-diamino-1,2-diphenylethane |
| E0346 |
| AKOS000120248 |
| 4-(4-aminophenethyl)benzenamine |
| A8596 |
| 4,4 inverted exclamation marka-ethylenedianiline |
| HMS2804F06 |
| ec 210-716-7 |
| 4-13-00-00401 (beilstein handbook reference) |
| FT-0617109 |
| SCHEMBL187043 |
| DTXSID3060742 |
| W-105034 |
| CHEMBL1704183 |
| AC-16755 |
| 4-[2-(4-aminophenyl)ethyl]phenylamine # |
| 4,4-ethylenedianiline |
| mfcd00007923 |
| AS-60549 |
| a,a'-bi-p-toluidine |
| 4,4'-(ethane-1,2-diyl)dianiline |
| F16584 |
| EN300-18238 |
| CS-0089167 |
| Z256707848 |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Protein Targets (3)
Potency Measurements
| Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| USP1 protein, partial | Homo sapiens (human) | Potency | 11.2202 | 0.0316 | 37.5844 | 354.8130 | AID743255 |
| DNA polymerase iota isoform a (long) | Homo sapiens (human) | Potency | 89.1251 | 0.0501 | 27.0736 | 89.1251 | AID588590 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
Other Measurements
| Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| FAD-linked sulfhydryl oxidase ALR | Homo sapiens (human) | AC50 | 1.9060 | 0.0050 | 3.2126 | 22.7870 | AID493248 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
Bioassays (11)
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID1745845 | Primary qHTS for Inhibitors of ATXN expression | |||
| AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
| AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
| AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
| AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
| AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
| AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
| AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
| AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
| AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
| AID651635 | Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression | |||
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
Research
Studies (7)
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (14.29) | 18.2507 |
| 2000's | 2 (28.57) | 29.6817 |
| 2010's | 3 (42.86) | 24.3611 |
| 2020's | 1 (14.29) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
Market Indicators
Research Demand Index: 12.59
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.59) All Compounds (24.57) |
Study Types
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 8 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||